Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2014—Primera Technology’s robotic-based, auto-loading version of the Signature Cassette Printer, model SCP-R, is now available. Signature Cassette Printer is designed for use in pathology and histology labs to print high-resolution text, graphics, and barcodes on tissue cassettes. It uses thermal transfer ink ribbons instead of solvent ink-jet or laser ablation.
February 2014—Crescendo Bioscience, a wholly owned subsidiary of Myriad Genetics, presented data that showed Vectra DA is a better predictor of radiographic progression over two years than other tests used to assess risk of joint damage in rheumatoid arthritis.
February 2014—The Clinical and Laboratory Standards Institute has released Nongynecological Cytology Specimens: Preexamination, Examination, and Postexamination Processes; Approved Guideline—Second Edition (GP23-A2). This document provides recommendations for cytology laboratories to use in developing preexamination, examination, and postexamination processes and procedures for nongynecological cytology specimens to ensure suitable specimens for diagnosis of cancer, infectious diseases, and other inflammatory conditions. CLSI, 610-688-0100
February 2014—BioTek Instruments introduced the Cytation 5 Cell Imaging Multi-Mode Reader. The cell imager combines automated digital widefield microscopy with conventional multimode microplate detection.
February 2014—AgileBio released an add-on for LabCollector called SNP Manager, which is dedicated to the treatment of single nucleotide polymorphism genotyping workflows. Users can generate picking lists and instructions files for tube pickers (Tube Sorter and Floyd 2D) and genotyping process (Fluidigm EP1) machines.
February 2014—The FDA has cleared Randox’s Acusera Liquid Assayed Chemistry Premium Plus, a multianalyte control containing 100 commonly used analytes, for use in U.S. laboratories. Randox believes the “super control” will revolutionize quality control in laboratories, saving time and money while ensuring accurate results and patient diagnosis.
February 2014—BioCision announced the availability of the ThawStar automated sample thawing system, designed to standardize the “last mile” in the cryopreservation process. Using the patent-pending Star sensing technology, the ThawStar system tailors the thaw cycle to the specific characteristics of each frozen sample.
February 2014—Beckman Coulter Diagnostics and Seegene announced a molecular diagnostic assay supply agreement. Under the agreement, Seegene will begin manufacturing reagents designed exclusively for Beckman Coulter’s Veris MDx System, a sample-to-answer molecular diagnostics instrument.
February 2014—Thermo Fisher Scientific has signed an agreement with Cynvenio Biosystems, a molecular testing company focused on the genomic analysis of tumor biomarkers in the bloodstream, for rights to distribute its LiquidBiopsy platform. The automated LiquidBiopsy platform is designed to extract and isolate circulating tumor cells from a standard blood draw in preparation for high-content imaging and genomic analysis.
February 2014—Siemens Healthcare announced the launch of its drug-testing platform designed to meet the productivity, workflow, and workspace needs of mid-volume laboratories—the Viva-ProE System with EMIT technology. The system features a benchtop design with a compact footprint for smaller workspaces, has a capacity for 50 sample and 12 auxiliary positions, and can run up to 133 EMIT tests per hour.
